These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29409111)

  • 1. Pre-operative core muscle index in combination with hypoalbuminemia is associated with poor prognosis in advanced ovarian cancer.
    Conrad LB; Awdeh H; Acosta-Torres S; Conrad SA; Bailey AA; Miller DS; Lea JS
    J Surg Oncol; 2018 Apr; 117(5):1020-1028. PubMed ID: 29409111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery.
    Ataseven B; du Bois A; Reinthaller A; Traut A; Heitz F; Aust S; Prader S; Polterauer S; Harter P; Grimm C
    Gynecol Oncol; 2015 Sep; 138(3):560-5. PubMed ID: 26163893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anesthetic selection and disease-free survival following optimal primary cytoreductive surgery for stage III epithelial ovarian cancer.
    Elias KM; Kang S; Liu X; Horowitz NS; Berkowitz RS; Frendl G
    Ann Surg Oncol; 2015 Apr; 22(4):1341-8. PubMed ID: 25287437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival.
    Ross MS; Burriss ME; Winger DG; Edwards RP; Courtney-Brooks M; Boisen MM
    Gynecol Oncol; 2018 Aug; 150(2):306-310. PubMed ID: 29929924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer.
    Kumar A; Moynagh MR; Multinu F; Cliby WA; McGree ME; Weaver AL; Young PM; Bakkum-Gamez JN; Langstraat CL; Dowdy SC; Jatoi A; Mariani A
    Gynecol Oncol; 2016 Aug; 142(2):311-6. PubMed ID: 27235857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer.
    Rutten IJG; Ubachs J; Kruitwagen RFPM; Beets-Tan RGH; Olde Damink SWM; Van Gorp T
    J Cachexia Sarcopenia Muscle; 2017 Aug; 8(4):630-638. PubMed ID: 28513088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery.
    Ataseven B; Luengo TG; du Bois A; Waltering KU; Traut A; Heitz F; Alesina PF; Prader S; Meier B; Schneider S; Koch JA; Walz M; Groeben HT; Nina P; Brunkhorst V; Heikaus S; Harter P
    Ann Surg Oncol; 2018 Oct; 25(11):3372-3379. PubMed ID: 30069659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery.
    Rutten IJ; Ubachs J; Kruitwagen RF; van Dijk DP; Beets-Tan RG; Massuger LF; Olde Damink SW; Van Gorp T
    Eur J Surg Oncol; 2017 Apr; 43(4):717-724. PubMed ID: 28159443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer.
    Kumar A; Langstraat CL; DeJong SR; McGree ME; Bakkum-Gamez JN; Weaver AL; LeBrasseur NK; Cliby WA
    Gynecol Oncol; 2017 Oct; 147(1):104-109. PubMed ID: 28734497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cancer.
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Pérez-Milán F; Ortiz-Quintana L
    Surg Oncol; 2014 Mar; 23(1):40-4. PubMed ID: 24183480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The preoperative albumin level is an independent prognostic factor for optimally debulked epithelial ovarian cancer.
    Ayhan A; Günakan E; Alyazıcı İ; Haberal N; Altundağ Ö; Dursun P
    Arch Gynecol Obstet; 2017 Nov; 296(5):989-995. PubMed ID: 28875365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of primary debulking in advanced ovarian cancer patients.
    Vlad C; Kubelac P; Alexandru I; Achimas-Cadariu P
    J BUON; 2016; 21(5):1320. PubMed ID: 27837639
    [No Abstract]   [Full Text] [Related]  

  • 13. Preoperative predictors that impact the survival and outcome of patients undergoing secondary cytoreduction for ovarian cancer.
    Katsnelson M; Hwang WT; Tahirovic E; Rubin SC; Tanyi JL
    J Obstet Gynaecol; 2018 Apr; 38(3):395-401. PubMed ID: 29385863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting non-home discharge in epithelial ovarian cancer patients: External validation of a predictive model.
    Connor EV; Newlin EM; Jelovsek JE; AlHilli MM
    Gynecol Oncol; 2018 Oct; 151(1):129-133. PubMed ID: 30107886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
    Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
    Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.
    Falcone F; Scambia G; Benedetti Panici P; Signorelli M; Cormio G; Giorda G; Bogliolo S; Marinaccio M; Ghezzi F; Rabaiotti E; Breda E; Casella G; Fanfani F; Di Donato V; Leone Roberti Maggiore U; Greggi S
    Gynecol Oncol; 2017 Oct; 147(1):66-72. PubMed ID: 28716306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
    Solmaz U; Mat E; Dereli ML; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
    J BUON; 2015; 20(3):847-54. PubMed ID: 26214639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
    Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
    J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: A prognostic analysis with 103 cases.
    Fan XM; Zhang J; Niu SH; Li KX; Song CZ
    Int J Surg; 2017 Feb; 38():61-66. PubMed ID: 28027999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.